Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.

Ga young Song,Sung-Hoon Jung,Je-Jung Lee,Jin Seok Kim,Chang-Ki Min,Kihyun Kim,Yunsuk Choi,Hyeon Seok Eom,Young-Don Joo,Sunghyun Kim,Jae-Yong Kwak,Hye Jin Kang,Jae Hoon Lee,Ho Sup Lee,Yeung-Chul Mun,Joon Ho Moon,Sang Kyun Sohn,Seong Kyu Park,Yong Park,Ho-Jin Shin,Sung-Soo Yoon

Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.

2020

We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients...

Keywords:

Busulfan
Medicine
Multiple myeloma
Diabetes mellitus
in patient
Autologous stem-cell transplantation
Oncology
Internal medicine
Immunology
Toxicity
Propensity score matching
Melphalan

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations